PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
First-line niraparib is associated with improvement in QA-PFS and QA-TWiST
Efficacy | ZEJULA (niraparib) for HCPs
Efficacy of niraparib in the PRIMA trial | Download Scientific Diagram
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial - Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana
PARP inhibitor in Ca Ovary | PPT
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study | Future Oncology
Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced
Efficacy | ZEJULA (niraparib) for HCPs
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer | Targeted Oncology
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab - ScienceDirect
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Current Oncology | Free Full-Text | A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study - Gynecologic Oncology
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
